BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 11983097)

  • 1. Nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Baron F; Beguin Y
    J Hematother Stem Cell Res; 2002 Apr; 11(2):243-63. PubMed ID: 11983097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minitransplants: allogeneic stem cell transplantation with reduced toxicity.
    Beguin Y; Baron F
    Acta Clin Belg; 2003; 58(1):37-45. PubMed ID: 12723260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hematological malignancies with allogeneic nonmyeloablative stem cell transplantation: conditioning regimens with fludarabine.
    Carella AM
    Hematol J; 2004; 5 Suppl 1():S68-75. PubMed ID: 15079155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nonmyeloablative stem cell transplantation as cancer immunotherapy].
    Willems E; Baron F; Vanstraelen G; Frère P; Fillet G; Beguin Y
    Rev Med Suisse; 2005 Aug; 1(30):1973-7. PubMed ID: 16200942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation.
    Champlin R; Khouri I; Anderlini P; Gajewski J; Kornblau S; Molldrem J; Shimoni A; Ueno N; Giralt S
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S13-22. PubMed ID: 11436116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-myeloablative transplants for malignant disease.
    Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
    Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells.
    Baron F; Baudoux E; Frère P; Tourqui S; Schaaf-Lafontaine N; Greimers R; Herens C; Fillet G; Beguin Y
    J Hematother Stem Cell Res; 2002 Apr; 11(2):301-14. PubMed ID: 11983101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Georges GE; Storb R
    Int J Hematol; 2003 Jan; 77(1):3-14. PubMed ID: 12568294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonmyeloablative allogeneic stem cell transplantation for acute leukemia.
    Laport GG
    Curr Hematol Rep; 2003 Jan; 2(1):49-56. PubMed ID: 12901154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
    Slavin S; Morecki S; Weiss L; Or R
    J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia.
    Qazilbash MH; Giralt SA; Champlin RE
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):703-13, xi. PubMed ID: 15271401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
    Michallet M; Dhedin N; Michallet AS
    Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.
    Banna GL; Aversa S; Sileni VC; Favaretto A; Ghiotto C; Monfardini S
    Crit Rev Oncol Hematol; 2004 Sep; 51(3):171-89. PubMed ID: 15331077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience.
    Shimoni A; Nagler A
    Curr Hematol Rep; 2004 Jul; 3(4):242-8. PubMed ID: 15217553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-myeloablative transplantation.
    Maloney DG; Sandmaier BM; Mackinnon S; Shizuru JA
    Hematology Am Soc Hematol Educ Program; 2002; ():392-421. PubMed ID: 12446434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
    Giralt S
    Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.